BACK TO FAESFARMA.COM
Investor's agenda
Upcoming events
All events

Newsletter

Subscribe to our newsletter

Welcome to our Investor’s corner, the FAES FARMA mailing list. If you want to be the first to find out about the most significant information affecting our company, please sign up by completing the following form.

    First Name *
    Last Name *
    Company
    ID Number
    Email *

    Privacy Policy

    Pursuant to the Organic Law on Data Protection of 15/1999 of 13 December, we inform you that the data you submit will now form part of a file owned by FAES FARMA S.A., for the purpose of keeping you informed about our company’s products and the activities we carry out.

    Accept

    Responsible FAES FARMA, S.A.+info
    Purpose To maintain the contact and communication with shareholders+info
    Legal capacity Consent from the user+info
    Recipients Responsibles for data treatment within the EU +info
    Rights Access, rectify and suppress data, as well as other rights, as explained in the further information field+info
    Origin The interested party themself +info
    Further information You can check further information detailed about Data Protection within our website: privacy policy
    Investor's corner
    Shareholders and Investors Contact

    As part of its commitment to transparency and rigorous information, FAES FARMA has established this section for our shareholders and investors. Here, we provide all the required information, as well as any other details the Company deems relevant regarding Corporate Governance practices.

    We have an email address and phone number for providing an effective service to everybody who has placed their trust in our company.

    Shareholders Contact

    accionistas@faesfarma.com

    Tel.: (+34) 900 922 554

    Avda. Autonomía, 10. 48940 Leoia (Vizcaya)

    Tel.: (+34) 94 481 83 00

    News
    Financial Reporting
    Go to News
    Economic and Financial News
    July 30th, 2026

    Faes Farma increases its revenue by 27% and posts a net profit of 57 million in the first half of the year, reaffirming its guidance for 2026

    The Group’s total revenue stands at 391.5 million euros (+27%), with the Farma division reaching 340 million euros (+28%), driven by international growth and the consolidation of the ophthalmology business. EBITDA reached […]

    Economic and Financial News
    July 1st, 2026

    Faes Farma advances its international expansion through an agreement to commercialise a new urology treatment in Latin America

    The company has signed an exclusive licensing and supply agreement with Dongkook Pharmaceutical to register and commercialize Uresco in 13 Latin American countries. The agreement includes a total amount of up to […]

    Economic and Financial News
    June 25th, 2026

    Faes Farma holds its Annual General Shareholders’ Meeting following a key year in the execution of its Strategic Plan

    Shareholders approved all items on the agenda, including the 2025 annual accounts, as well as the appointment of Jacobo Llanza and Ángel Agudo as members of the Board of Directors. The Meeting […]

    Economic and Financial News
    April 30th, 2026

    Faes Farma exceeds €200 million in revenue (+31%) and increases its net profit by +9% in the first quarter

    Revenue grew by +31%, exceeding guidance, driven by the strength of international markets, both in direct sales and licensing, alongside acquisitions. The Pharma business reached €175 million (+31%), with ophthalmology establishing itself […]

    Economic and Financial News
    February 26th, 2026

    Faes Farma increases its revenue by 23% to €627 million

    Strong performance across all business areas enabled the company to close the 2025 financial year with organic revenue above guidance and adjusted EBITDA in line with expectations. The Pharma division achieved double-digit […]

    Economic and Financial News
    November 4th, 2025

    Faes Farma increases its revenue by more than 15% to €454 million

    The company exceeds its revenue forecasts for the year as a whole thanks to the strong performance across all business areas The Pharma division posts double-digit growth (+13%) driven by strong performance […]

    Economic and Financial News
    September 2nd, 2025

    Faes Farma completes the acquisition of SIFI and consolidates its international leadership in ophthalmology

    The transaction reinforces the Group’s new global strategy and boosts ophthalmology as one of its key growth areas. Thanks to this transaction and the acquisition of Edol in March, ophthalmology will account […]

    Economic and Financial News
    July 24th, 2025

    Faes Farma increases revenue by 12.3% to €307.4 million

    The pharmaceutical business grew by +9% to €269 million, with international markets (+14%) and licenses (+13%) continuing to be the main drivers of growth. The three strategic molecules (Bilastine, Calcifediol and Mesalazine) […]

    Economic and Financial News
    July 16th, 2025

    Faes Farma’s Shareholders’ Meeting approves the acquisition of 100% of SIFI

    Shareholder support consolidates the transaction as a transformational step for the company’s strategy The acquisition consolidates Faes Farma as a leading ophthalmology company with one of the most comprehensive offerings in the […]

    Economic and Financial News
    June 25th, 2025

    Faes Farma reaffirms its ambition and strategic plan to 2030 to its shareholders

    The Meeting approves the payment of a final dividend of 0.138 euros per share on July 7, for a total dividend of 0.179 euros per share, a pay-out of 51%. All items […]

    error: